Vaccinex stock fell 1.94 percent to USD 1.01 at OTC Markets

Published on 10/05/2026 at 14:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vaccinex stock traded at USD 1.01 on OTC Markets on October 2, 2026, after a 1.94 percent daily decline. Market capitalization stood at USD 2.7 million.

VCNX, US9186403013, Illustration mit AI erstellt.

Vaccinex (ISIN US9186403013) was last at USD 1.01 on OTC Markets on October 2, 2026, down 1.94 percent from the prior close. The small-cap biotechnology company is centered on pepinemab, an antibody candidate aimed at neuroinflammation and cancer applications.

Pepinemab anchors the pipeline

According to Vaccinex, pepinemab inhibits semaphorin 4D, or SEMA4D, a target the company associates with neuroinflammation. The investor page identifies Huntington disease and Alzheimer disease as neurology applications and also describes potential use with checkpoint inhibitors in oncology.

The company also presents ActivMAb as a proprietary drug discovery platform for future pipeline expansion and strategic collaborations, according to Vaccinex. That structure leaves clinical progress and partnership activity as the central operating variables behind the equity story.

Historical revenue shows early scale

Vaccinex reported historical fiscal year 2024 revenue of USD 601,000, according to ToAlpha. The same page lists Q4 2024 revenue of USD 213,000, a 965.0 percent increase from the comparable period, and diluted EPS of negative USD 0.01.

Q4 2024 net loss was USD 3.374 million, while operating margin was negative 1,590.1 percent, the historical filing summary reports. The comparison between USD 213,000 of quarterly revenue and USD 3.374 million of net loss highlights the distance between commercial revenue and the cost base at that stage.

These figures are historical rather than a current quarterly update. They still frame the market value: investors are valuing a development-stage biotechnology business primarily through its pipeline potential, not through established product sales.

Stock stays below yearly high

At USD 1.01, Vaccinex stock stood 32.67 percent below its 52-week high of USD 1.50 on October 2, 2026. The same range extends down to USD 0.31, placing the last quote USD 0.70 above the yearly low.

Market capitalization was USD 2.7 million on October 2, 2026, and trading volume was 101 shares. The combination of a USD 1.01 quote, a USD 2.7 million market value and a wide USD 0.31 to USD 1.50 annual range points to a thinly traded security where individual sessions can carry disproportionate weight.

For investors, the key reading is the gap between the development program described by Vaccinex and the historical revenue base documented by its filings. Pepinemab and ActivMAb supply the strategic narrative, while the financial figures show a company still operating at an early commercial scale.

OTC quote sets the reference

Vaccinex stock was last at USD 1.01 on OTC Markets on October 2, 2026 at 4:00 p.m. ET, with a daily change of negative 1.94 percent. Its market capitalization was USD 2.7 million on that date.